Amgen’s Aranesp Reimbursement Continues To Get Scrutiny From Capitol Hill

The debate around Medicare reimbursement for Amgen's anemia treatments Aranesp and Epogen is being reopened by House Ways & Means Committee Chairman Bill Thomas (R-Calif.) as CMS drafts its annual payment update rule that addresses the issue